|
|
Last Modified: 12/1/2008  First Published: 8/5/2005 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Prevention
|
|
|
|
Closed
|
|
|
|
18 to 25
|
|
|
|
NCI
|
|
|
|
NCI-04-C-N191 NCI-590299/009, GSK-590299/009, NCT00128661
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Biomarker/Laboratory analysis, Prevention
|
|
|
|
Completed
|
|
|
|
18 to 25
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
104772 NCT00250276
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Biomarker/Laboratory analysis, Prevention
|
|
|
|
Closed
|
|
|
|
26 and older
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
104820 NCT00294047
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Biomarker/Laboratory analysis, Prevention
|
|
|
|
Completed
|
|
|
|
18 to 35
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
106001 NCT00306241
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Natural history/Epidemiology, Prevention
|
|
|
|
Closed
|
|
|
|
10 to 25
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
107476 (M18) 107477 (M24), 107479 (M36), 107481 (M48), NCT00337818
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Prevention
|
|
|
|
Completed
|
|
|
|
18 to 35
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
104479 NCT00344032
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Biomarker/Laboratory analysis, Prevention
|
|
|
|
Completed
|
|
|
|
18 to 35
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
105926 NCT00345878
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Natural history/Epidemiology, Prevention
|
|
|
|
Closed
|
|
|
|
10 to 14
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
104896 (month 18 FU) 104902 (month 24 FU), 104904 (month 36 FU), 104918 (month 48 FU), NCT00316706
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Natural history/Epidemiology, Prevention
|
|
|
|
Completed
|
|
|
|
11 to 18
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
107682 NCT00369824
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Biomarker/Laboratory analysis, Prevention
|
|
|
|
Completed
|
|
|
|
18 to 45
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
108933 NCT00423046
|
|
|
|